© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The antibody-drug conjugate extended survival by four months compared with chemotherapy.
The 30% improvement in survival has brought a Phase III trial to an early halt.
Last year, the FDA approved three new antibody-drug conjugates for treating cancer.
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
